NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis $6.49 -0.22 (-3.28%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.50 +0.00 (+0.08%) As of 07/25/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Personalis Stock (NASDAQ:PSNL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Personalis alerts:Sign Up Key Stats Today's Range$6.40▼$6.7050-Day Range$4.59▼$7.5652-Week Range$2.81▼$7.79Volume590,736 shsAverage Volume1.64 million shsMarket Capitalization$573.20 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingBuy Company Overview Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. Read More Personalis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScorePSNL MarketRank™: Personalis scored higher than 71% of companies evaluated by MarketBeat, and ranked 308th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 2 research reports in the past 90 days.Read more about Personalis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.40) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Personalis' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.23% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Personalis has recently increased by 59.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.66 Percentage of Shares Shorted7.23% of the float of Personalis has been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Personalis has recently increased by 59.07%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.18 News SentimentPersonalis has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Personalis this week, compared to 3 articles on an average week.Search Interest5 people have searched for PSNL on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Personalis to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,186.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Personalis' insider trading history. Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address PSNL Stock News HeadlinesPersonalis to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | businesswire.comHead-To-Head Contrast: Personalis (NASDAQ:PSNL) & Acura Pharmaceuticals (OTCMKTS:ACUR)July 18, 2025 | americanbankingnews.comIt’s my duty to share the “truth” I see behind this bible verseFormer CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 trillion “birthright” tied to America’s untouched wealth. He says the Book of Genesis predicted this moment… and those who act now could be first in line to benefit. The full presentation is now live.July 26 at 2:00 AM | Paradigm Press (Ad)Personalis, Inc. (PSNL) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comPersonalis and Tempus extend cancer detection collaboration to 2029July 11, 2025 | investing.comPersonalis Expands Tempus Strategic Collaboration to Bring Ultra ...July 11, 2025 | morningstar.comMPersonalis, Tempus Expand Detection Test to Include Colorectal CancerJuly 9, 2025 | marketwatch.comStocks to Watch: Nurix Therapeutics, Personalis, WK KelloggJuly 9, 2025 | marketwatch.comSee More Headlines PSNL Stock Analysis - Frequently Asked Questions How have PSNL shares performed this year? Personalis' stock was trading at $5.78 at the beginning of the year. Since then, PSNL stock has increased by 12.3% and is now trading at $6.49. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) posted its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business earned $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative net margin of 98.10% and a negative trailing twelve-month return on equity of 48.78%. Read the conference call transcript. When did Personalis IPO? Personalis (PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Top institutional shareholders of Personalis include Aberdeen Group plc (1.99%). Insiders that own company stock include Christopher M Hall, Aaron Tachibana, Richard Chen, Stephen Michael Moore and Stephen Michael Moore. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Unity Software (U) and Vuzix (VUZI). Company Calendar Last Earnings5/06/2025Today7/26/2025Next Earnings (Confirmed)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryHealthcare Current SymbolNASDAQ:PSNL CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Price Target for Personalis$7.67 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside+18.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.28 million Net Margins-98.10% Pretax Margin-98.08% Return on Equity-48.78% Return on Assets-34.70% Debt Debt-to-Equity RatioN/A Current Ratio6.91 Quick Ratio6.74 Sales & Book Value Annual Sales$84.61 million Price / Sales6.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book2.26Miscellaneous Outstanding Shares88,320,000Free Float84,969,000Market Cap$573.20 million OptionableOptionable Beta1.95 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:PSNL) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.